Market Mover: Foghorn (FHTX) Climbs at Midday June 21

Equities Staff  |

Foghorn Therapeutics Inc (NASDAQ: FHTX) shares moved 9.53%, or $1.14 per share, as on 11:54:54 est today. Since opening at $12.28, 44,045 shares of Foghorn exchanged hands and the stock has traded between $13.52 and $12.28.  

So far this year the company is down 47.70%.

Foghorn is set to release earnings on 2022-08-10.

For technical charts, analysis, and more on Foghorn visit the company profile.

About Foghorn Therapeutics Inc

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. The Company's proprietary Gene Traffic Control® platform gives it an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system.

To get more information on Foghorn Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Foghorn Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content